Aurora Kinase Inhibitor Pipeline Report 2021 - ResearchAndMarkets.com

The "Aurora Kinase Inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This "Aurora Kinase Inhibitor - Pipeline Insight, 2021" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Aurora Kinase Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Aurora Kinase Inhibitor Emerging Drugs Chapters

This segment of the Aurora Kinase Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Aurora Kinase Inhibitor Emerging Drugs

Alisertib: Takeda Oncology

Alisertib (MLN8237) is an oral, selective, inhibitor of Aurora A kinase being investigated by Takeda for the treatment of small cell lung cancer. Aurora A kinase is required for cells to divide properly and has been shown to be over-expressed in a variety of cancers, and inhibition of Aurora A kinase represents a novel approach in cancer research. The drug is currently in phase 2 stage of development for the treatment of Acute myeloid leukaemia.

Chiauranib: Chipscreen Biosciences

Chiauranib has a new chemical structure which is under global patent protection. The compound is independently designed and developed by Chipscreen Biosciences. It is a highly-selective Aurora B, CSF1R, VEGFR/PDGFR/c-Kit inhibitor, which exerts a comprehensive anti-tumor effect by simultaneously inhibiting tumor angiogenesis, inhibiting tumor cell mitosis and regulating tumor microenvironment. Chiauranib has shown pharmacological activity superior to that of other similar drugs in animal studies.

In the meantime, it has an excellent safety profile despite being a multi-target kinase inhibitor. Chiauranib as a single agent therapy inhibits the overactive Aurora B pathway existed in and related to molecular mechanism of SCLC, which is an important feature of Chiauranib distinct to other antiangiogenic drugs. The drug is currently in phase 3 stage of development for the treatment of Small cell lung cancer.

Aurora Kinase Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Aurora Kinase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Aurora Kinase Inhibitor

There are approx. 10+ key companies which are developing the Aurora Kinase Inhibitor. The companies which have their Aurora Kinase Inhibitor drug candidates in the most advanced stage, i.e. phase III include, Chipscreen Biosciences.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Aurora Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Aurora Kinase Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Aurora Kinase Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aurora Kinase Inhibitor drugs.

Aurora Kinase Inhibitor Report Insights

• Aurora Kinase Inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Aurora Kinase Inhibitor Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Scenario and Emerging Therapies:

• How many companies are developing Aurora Kinase Inhibitor drugs?
• How many Aurora Kinase Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Aurora Kinase Inhibitor?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Aurora Kinase Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Aurora Kinase Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Takeda Oncology
• Chipscreen Biosciences
• Aptose Biosciences
• Eli Lilly and Company
• AstraZeneca
• Nerviano Medical Sciences
• Advenchen Laboratories
• TransThera Biosciences
• Abbott Laboratories
• Sumitomo Dainippon Pharma Oncology
• GlaxoSmithKline
• Sareum

Key Products

• Alisertib
• Chiauranib
• Luxeptinib
• AK 01
• AZD 2811
• Danusertib
• AL 8326
• TT 00420
• Ilorasertib
• Dubermatinib
• GSK-1070916

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/71d7kq

View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005266/en/